| Full Name | Tamar Nir |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 840 Ne 125th St, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225723489 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL61222104 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tamar Nir, 840 Ne 125th St, Seattle, WA 98125-3970 Ph: (954) 376-1473 | Tamar Nir, 840 Ne 125th St, Seattle, WA 98125-3970 Ph: (954) 376-1473 |
News Archive
A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count-a key measure of immune system health-is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV.
Long-term acute care facilities are designed to meet the needs of older adults with severe, complex illnesses who are recovering from hospitalization, but less expensive options sometimes overlooked may also be available, population health researchers at UT Southwestern found.
An experimental malaria drug was shown to effectively treat the disease in mice with only a single dose, according to a study published Thursday in the journal Science, Reuters reports (Kelland, 9/2). The new drug, known as NITD609, "represents an entirely new class of medicines to treat malaria ... Human trials, backed by Swiss pharmaceutical giant Novartis AG, could begin later this year," the Wall Street Journal writes (Naik, 9/3).
Liquid biopsy, the detection of circulating disease biomarkers in bodily fluids such as blood, is a non-invasive method, alternative to tissue removal, which has taken important strides toward the implementation of personalized medicine, especially in the case of tumors and RNA-viruses.
Further to a Letter of Intent previously reported, Genesis Bioventures today announced that it has entered into a binding agreement with Efoora Inc. and Prion Developmental Laboratories, Inc. to buy all of Efoora's majority interest shares owned or pledged in PDL thereby gaining controlling interest of PDL. A Form 8-K has been filed with the SEC in this regard. Prior to the Agreement, GBI had one-third equity interest in PDL.
› Verified 4 days ago
Amy L Donaldson, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Autism Ctr, Box 357920, Seattle, WA 98195 Phone: 206-897-1801 | |
Ms. Carol L Ray, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4507 Sunnyside Ave N, Unit D, Seattle, WA 98103 Phone: 206-849-3937 | |
Ms. Linda E Eblen, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4800 Sand Point Way Ne, Mail Stop W-6839, Seattle, WA 98105 Phone: 206-987-6164 | |
Mrs. Genevieve Houdet-cote, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Ms:h4-pmr, Seattle, WA 98101 Phone: 206-341-0461 | |
Daelene King, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9100 5th Ave Ne, Seattle, WA 98115 Phone: 206-526-2662 | |
Molly Beier, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-744-3000 | |
Vassalo Speech And Language Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2300 W Bertona St, Seattle, WA 98199 Phone: 978-444-0321 |